News | May 27, 2026
Siegfried locks in CHF 200m bond deal as investors bet big on pharma outsourcing boom
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
